In this instance, the partnership will combine Senseonics’ Eversense continuous glucose monitor (CGM), TypeZero’s InControl algorithms, and Roche’s Accu-Chek Insight Insulin Pump.

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Find the latest Endocrinology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.